|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Residual renal function in peritoneal dialysis with failed allograft and minimum immunosuppression显示文摘Immunosuppression(IS) is often withdrawn in patients with end stage renal disease secondary to a failed renal allograft, and this can lead to an accelerated loss of residual renal function(RRF). As maintenance of RRF appears to provide a survival benefit to peritoneal dialysis(PD) patients, it is not clear whether this benefit of maintaining RRF in failed allograft patients returning to PD outweigh the risks of maintaining IS. A 49 year-old Caucasian male developed progressive allograft failure nine years after living-donor renal transplantation. Hemodialysis was initiated via tunneled dialysis catheter(TDC) and IS was gradually withdrawn. Two weeksafter IS withdrawal he developed a febrile illness, which necessitate removal of the TDC and conversion to PD. He was maintained on small dose of tacrolimus(1 mg/d) and prednisone(5 mg/d). Currently(1 year later) he is doing exceedingly well on cycler-assisted PD. Residual urine output ranges between 600-1200 m L/d. Total weekly Kt/V achieved 1.82. RRF remained well preserved in this patient with failed renal allograft with minimal immunosuppressive therapy. This strategy will need further study in well-defined cohorts of PD patients with failed allografts and residual RRF to determine efficacy and safety. | Nadear Elmahi éva Csongrádi Kenneth Kokko Jack R Lewin Jamie Davison Tibor Fülp | 2013 | World Journal of Transplantation2013，3，2： | 5 |
| 2 | Biological therapy in inflammatory bowel diseases:Access in Central and Eastern Europe显示文摘Biological drugs opened up new horizons in the management of inflammatory bowel diseases(IBD).This study focuses on access to biological therapy in IBD patients across 9 selected Central and Eastern European(CEE)countries,namely Bulgaria,the Czech Republic,Estonia,Hungary,Latvia,Lithuania,Poland,Romania and Slovakia.Literature data on the epidemiology and disease burden of IBD in CEE countries was systematically reviewed.Moreover,we provide an estimation on prevalence of IBD as well as biological treatment rates.In all countries with the exception of Romania,lower biological treatment rates were observed in ulcerative colitis(UC)compared to Crohn’s disease despite the higher prevalence of UC.Great heterogeneity(up to 96-fold)was found in access to biologicals across the CEE countries.Poland,Bulgaria,Romania and the Baltic States are lagging behind Hungary,Slovakia and the Czech Republic in their access to biologicals.Variations of reimbursement policy may be one of the factors explaining the differences to a certain extent in Bulgaria,Latvia,Lithuania,and Poland,but association with other possible determinants(differences in prevalence and incidence,price of biologicals,total expenditure on health,geographical access,and cost-effectiveness results)was not proven.We assume,nevertheless,that healthdeterioration linked to IBD might be valued differently against other systemic inflammatory conditions in distinct countries and which may contribute to the immense diversity in the utilization of biological drugs for IBD.In conclusion,access to biologicals varies widely among CEE countries and this difference cannot be explained by epidemiological factors,drug prices or total health expenditure.Changes in reimbursement policy could contribute to better access to biologicals in some countries. | Fanni Rencz Márta Péntek Martin Bortlik Edyta Zagorowicz Tibor Hlavaty Andrzej Sliwczyński Mihai M Diculescu Limas Kupcinskas Krisztina B Gecse László Gulácsi Peter L Lakatos | 2015 | World Journal of Gastroenterology2015，21，6： | 4 |
| 3 | Minimization vs tailoring:Where do we stand with personalized immunosuppression during renal transplantation in 2015?显示文摘The introduction of novel immunosuppressive agents over the last two decades and the improvement of our diagnostic tools for early detection of antibodymediated injury offer us an opportunity, if not a mandate, to better match the immunosuppression needs of the individual patients with side effects of the therapy. However, immunosuppressive regimens in the majority of programs remain mostly protocol-driven, with relatively little inter-program heterogeneity in certain areas of the world. Emerging data showing different outcomes with a particular immunosuppressive strategy in populations with varying immunological risks underscore a real potential for 'personalized medicine' in renal transplantation. Studies demonstrating marked differences in the adverse-effect profiles of individual drugs including the risk for viral infections, malignancy and renal toxicity call for a paradigm shift away from a 'one size fits all' approach to an individually tailored immunosuppressive therapy for renal transplant recipients, assisted by both screening for predictors of graft loss and paying close attention to dose or class-related adverse effects. Our paper explores some of the opportunities during the care of these patients. Potential areas of improvements may include:(1) a thorough assessment of immunological and metabolic risk profile of each renal transplant recipient;(2) screening for predictors of graft loss and early signs of antibody-mediated rejection with donor-specific antibodies, protocol biopsies and proteinuria(including close follow up of adverse effects with dose adjustments or conversions as necessary); and(3) increased awareness of the possible link between poor tolerance of a given drug at a given dose and non-adherence with the prescribed regimen. Altogether, these considerations may enable the most effective use of the drugs we already have. | Lajos Zsom László Wagner Tibor Fül?p | 2015 | World Journal of Transplantation2015，5，3： | 3 |
| 4 | Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy显示文摘AIM:To assess the endoscopic activity before and after a one-year period of biological therapy and to evaluate the frequency of relapses and need for retreatment after stopping the biologicals in patients with Crohn’s disease(CD)and ulcerative colitis(UC).METHODS:The data from 41 patients with CD and 22 patients with UC were assessed.Twenty-four CD patients received infliximab,and 17 received adalimumab.The endoscopic severity of CD was quantified with the simplified endoscopic activity score for Crohn’s disease in CD and with the Mayo endoscopic subscore in UC.RESULTS:Mucosal healing was achieved in 23 CD and7 UC patients.Biological therapy had to be restarted in78%of patients achieving complete mucosal healing with CD and in 100%of patients with UC.Neither clinical remission nor mucosal healing was associated with the time to restarting the biological therapy in either CD or UC.CONCLUSION:Mucosal healing did not predict sustained clinical remission in patients in whom the biological therapies had been stopped. | Klaudia Farkas Péter László Lakatos Mónika Szcs va Pallagi-Kunstár Anita Bálint Ferenc Nagy Zoltán Szepes Noémi Vass Lajos S Kiss Tibor Wittmann Tamás Molnár | 2014 | World Journal of Gastroenterology2014，20，11： | 2 |
| 5 | Frotectlon o Balb/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG o;Igodeoxynucletides as adjuvant显示文摘 | Mariri AL Tibor A Mertens Mertens P et 81 | 2001 | Infect Immune2001，69，8： | 1 |
| 6 | Protection of Balb/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant显示文摘 | Mariri A L Tibor A Mertens P | 2001 | Infect Immun2001，69，： | 1 |
| 7 | Design of potent, non-toxic antimicrobial agents based upon the structure of the frog skin peptide, pseudin-2显示文摘 | Tibor Pál ágnes Sonnevend Sehamuddin Galadari J. Michael Conlon | 2005 | Regulatory Peptides2005，，1： | 1 |
| 8 | Microwave photonics-a his-torical perspective 显示文摘 | Tibor Berceli Herczfeld P R | 2010 | IEEE transactions on microwave theory and techiques2010，58，： | 1 |
| 9 | Protection of Balb/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG o; Igodeoxynucleotides as adjuvant 显示文摘 | Tibor A Mertens Mertens P | 2001 | Infect Immun2001，69，8： | 1 |
| 10 | Pancreatic head mass: How can we treat it? Tumor: Surgical treatment显示文摘 | Tibor FT Istvan P Tamas W | 2000 | JOP J Pancreas2000，1，2： | 1 |
| 11 | Humoral immune responses of Brucella-infected cattle, sheep, and goats to eight purified recombinant Brucella proteins in an indirect enzyme-linked immunosorbent assay 显示文摘 | Letesson JJ Tibor A van Eynde G Wansard V Weynants V Denoel P Saman E | 1997 | Clin Diagn Lab Immunol1997，4，5： | 1 |
| 12 | Molecular characterization, occurrence, and immunogenicity in infected sheep and cattle of two minor outer membrane proteins of Brucella abortus 显示文摘 | Tibor A Saman E de Wergifosse P Cloeckaert A Limet IN Letesson JJ | 1996 | Infect Immun1996，64，1： | 1 |
| 13 | Capacitive sensor for active tip clearance control in a palm-sized gas turbine generator 显示文摘 | Tibor Fabian Friedrich B P | 2005 | IEEE Transaction on Instrumentation and Measurement2005，54，3： | 1 |
| 14 | Detection of Yersinia enterocolitica Serogroup O -' 3 by a PCR Method显示文摘 | Weynants V Jadot V Denoe Tibor A Letesson J J | 1996 | J Clin Microbiol1996，，： | 1 |
| 15 | Ins,outs,and the duration of trade显示文摘 | TIBOR B TOMAS J P | 2006 | Canadian Journal of Economics2006，39，1： | 1 |
| 16 | Product differentiation and duration of US import trade显示文摘 | TIBOR B TOMAS J P | 2006 | Journal Of International Economics2006，，70： | 1 |
| 17 | Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant显示文摘 | Al-Mariri A Tibor A Mertens P | 2001 | Infect Immun2001，69，8： | 1 |
| 18 | Insect feeding mobilizes a unique plant defense protease that disrupts the peritrophic matrix of caterpillars显示文摘 | Tibor P Allen C Willianms W P | 2002 | Plant Biology2002，99，13： | 1 |
| 19 | Brucella pathogenesis, genes identified, from random large-scale screens显示文摘 | DELRUE R M LESTRATE P TIBOR A | 2004 | FEMS Microbiol Lett2004，231，1： | 1 |
| 20 | Brucella pathogenesis, genes identified from random large-scale screens 显示文摘 | Delrue RM Lestrate P Tibor A | 2004 | FEMS Microbiol Lett2004，231，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员